Lv6
1790 积分 2021-01-25 加入
Olverembatinib in chronic myeloid leukemia—Review of historical development, current status, and future research
2天前
已完结
A new face in the treatment of Philadelphia chromosome‐positive acute lymphoblastic leukaemia
2天前
已关闭
Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Region–Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance against Imatinib
2天前
已完结
Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial
2天前
已完结
Efficacy and Safety of the Third‐Generation Tyrosine Kinase Inhibitor Olverembatinib in Combination With Inotuzumab Ozogamicin for the Treatment of Adult Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia Patients With Refractory/Relapsed Disease or Persistent Minimal Residual Disease Bridging to Hematopoietic Stem Cell Transplantation
2天前
已完结
BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia
1个月前
已关闭
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia
1个月前
已完结
Olverembatinib in chronic myeloid leukemia—Review of historical development, current status, and future research
4个月前
已完结
Considerations on the Dose and Schedule of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: Does Dose Matter?
4个月前
已关闭
Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia
5个月前
已完结
皖公网安备34019202002308
